placebo + Arnica and Bryonia
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Aortic Valve Replacement
Conditions
Aortic Valve Replacement
Trial Timeline
Sep 1, 2004 → Aug 1, 2007
NCT ID
NCT00774293About placebo + Arnica and Bryonia
placebo + Arnica and Bryonia is a approved stage product being developed by Boiron for Aortic Valve Replacement. The current trial status is completed. This product is registered under clinical trial identifier NCT00774293. Target conditions include Aortic Valve Replacement.
What happened to similar drugs?
5 of 13 similar drugs in Aortic Valve Replacement were approved
Approved (5) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00774293 | Approved | Completed |
Competing Products
20 competing products in Aortic Valve Replacement
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 26 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 36 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 43 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 35 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 40 |
| candesartan + placebo | AstraZeneca | Phase 3 | 36 |
| Sugammadex | Merck | Approved | 43 |
| bisoprolol + placebo | Merck | Approved | 35 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 42 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 42 |
| fluvastatin | Novartis | Phase 2 | 31 |
| ACZ885 + Placebo | Novartis | Phase 2 | 27 |
| Evolocumab + Placebo | Amgen | Phase 1 | 36 |
| atorvastatin (Lipitor) | Pfizer | Approved | 35 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 40 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 29 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 35 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 35 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 29 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 37 |